206 related articles for article (PubMed ID: 19387319)
21. Fibroblast growth factor-23 in patients with Graves' disease before and after antithyroid therapy: its important role in serum phosphate regulation.
Yamashita H; Yamazaki Y; Hasegawa H; Yamashita T; Fukumoto S; Shigematsu T; Kazama JJ; Fukagawa M; Noguchi S
J Clin Endocrinol Metab; 2005 Jul; 90(7):4211-5. PubMed ID: 15827108
[TBL] [Abstract][Full Text] [Related]
22. Acid Load and Phosphorus Homeostasis in CKD.
Khairallah P; Isakova T; Asplin J; Hamm L; Dobre M; Rahman M; Sharma K; Leonard M; Miller E; Jaar B; Brecklin C; Yang W; Wang X; Feldman H; Wolf M; Scialla JJ;
Am J Kidney Dis; 2017 Oct; 70(4):541-550. PubMed ID: 28645705
[TBL] [Abstract][Full Text] [Related]
23. Earlier decrease of FGF-23 and less hypophosphatemia in preemptive kidney transplant recipients.
Barros X; Torregrosa JV; Martínez de Osaba MJ; Casals G; Paschoalin R; Durán CE; Campistol JM
Transplantation; 2012 Oct; 94(8):830-6. PubMed ID: 23018879
[TBL] [Abstract][Full Text] [Related]
24. Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss.
Kanaan N; Claes K; Devogelaer JP; Vanderschueren D; Depresseux G; Goffin E; Evenepoel P
Clin J Am Soc Nephrol; 2010 Oct; 5(10):1887-92. PubMed ID: 20634326
[TBL] [Abstract][Full Text] [Related]
25. Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism.
Serra AL; Wuhrmann C; Wüthrich RP
Am J Kidney Dis; 2008 Dec; 52(6):1151-7. PubMed ID: 18950915
[TBL] [Abstract][Full Text] [Related]
26. Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases.
Imanishi Y; Kobayashi K; Kawata T; Inaba M; Nishizawa Y
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S32-7. PubMed ID: 17976083
[TBL] [Abstract][Full Text] [Related]
27. Fibroblast growth factor 23, but not parathyroid hormone, is associated with urinary phosphate regulation in patients on peritoneal dialysis.
Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Hasegawa S; Tanaka S; Eriguchi M; Nakano T; Masutani K; Ooboshi H; Kitazono T
Ther Apher Dial; 2015 Feb; 19(1):73-80. PubMed ID: 25195562
[TBL] [Abstract][Full Text] [Related]
28. Serum phosphate and phosphate-regulatory hormones in COPD patients.
Stroda A; Brandenburg V; Daher A; Cornelissen C; Goettsch C; Keszei A; Dreher M
Respir Res; 2018 Sep; 19(1):183. PubMed ID: 30236113
[TBL] [Abstract][Full Text] [Related]
29. Cinacalcet in the management of tumor-induced osteomalacia.
Geller JL; Khosravi A; Kelly MH; Riminucci M; Adams JS; Collins MT
J Bone Miner Res; 2007 Jun; 22(6):931-7. PubMed ID: 17352646
[TBL] [Abstract][Full Text] [Related]
30. Phosphate handling by end-stage kidneys and benefits of residual renal function on phosphate removal in patients on haemodialysis.
Iwasawa H; Nakao T; Matsumoto H; Okada T; Nagaoka Y; Wada T
Nephrology (Carlton); 2013 Apr; 18(4):285-91. PubMed ID: 23432763
[TBL] [Abstract][Full Text] [Related]
31. Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia.
Green J; Debby H; Lederer E; Levi M; Zajicek HK; Bick T
Kidney Int; 2001 Sep; 60(3):1182-96. PubMed ID: 11532115
[TBL] [Abstract][Full Text] [Related]
32. Hypophosphatemia: an update on its etiology and treatment.
Gaasbeek A; Meinders AE
Am J Med; 2005 Oct; 118(10):1094-101. PubMed ID: 16194637
[TBL] [Abstract][Full Text] [Related]
33. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women.
Burnett SM; Gunawardene SC; Bringhurst FR; Jüppner H; Lee H; Finkelstein JS
J Bone Miner Res; 2006 Aug; 21(8):1187-96. PubMed ID: 16869716
[TBL] [Abstract][Full Text] [Related]
34. Association of circulating fibroblast growth factor-23 with renal phosphate excretion among hemodialysis patients with residual renal function.
Wang M; You L; Li H; Lin Y; Zhang Z; Hao C; Chen J
Clin J Am Soc Nephrol; 2013 Jan; 8(1):116-25. PubMed ID: 23085728
[TBL] [Abstract][Full Text] [Related]
35. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.
Ferrari SL; Bonjour JP; Rizzoli R
J Clin Endocrinol Metab; 2005 Mar; 90(3):1519-24. PubMed ID: 15613425
[TBL] [Abstract][Full Text] [Related]
36. Oral phosphate supplementation corrects hypophosphatemia and normalizes plasma FGF23 and 25-hydroxyvitamin D3 levels in women with chronic metabolic acidosis.
Domrongkitchaiporn S; Disthabanchong S; Cheawchanthanakij R; Niticharoenpong K; Stitchantrakul W; Charoenphandhu N; Krishnamra N
Exp Clin Endocrinol Diabetes; 2010 Feb; 118(2):105-12. PubMed ID: 19449283
[TBL] [Abstract][Full Text] [Related]
37. Fibroblast growth factor 23 in feline chronic kidney disease.
Geddes RF; Finch NC; Elliott J; Syme HM
J Vet Intern Med; 2013; 27(2):234-41. PubMed ID: 23398216
[TBL] [Abstract][Full Text] [Related]
38. The human response to acute enteral and parenteral phosphate loads.
Scanni R; vonRotz M; Jehle S; Hulter HN; Krapf R
J Am Soc Nephrol; 2014 Dec; 25(12):2730-9. PubMed ID: 24854273
[TBL] [Abstract][Full Text] [Related]
39. Fibroblast growth factor 23 (FGF23) and the kidney.
Tsagalis G; Psimenou E; Manios E; Laggouranis A
Int J Artif Organs; 2009 Apr; 32(4):232-9. PubMed ID: 19569031
[TBL] [Abstract][Full Text] [Related]
40. Chronic respiratory alkalosis induces renal PTH-resistance, hyperphosphatemia and hypocalcemia in humans.
Krapf R; Jaeger P; Hulter HN
Kidney Int; 1992 Sep; 42(3):727-34. PubMed ID: 1405350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
